Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application ...

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

The first sock measuring shear stress aimed at reducing the risk of foot ulcers for patients with diabetes is among several innovations being ...

Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent ...

Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced ...

Researchers have developed an experimental wound dressing for diabetic ulcers using biological material made by human cells, ...

WRITTEN BY ANNE GABBIANELLI According to the American Podiatric Medical Association, at least 75% of Americans will ...

FibroBiologics Inc. FBLG on Monday released the first batch of its CYWC628 drug product to support its Phase 1/2 clinical ...

The U.S. Wound Cleanser Products Market is projected to grow from USD 0.99 Billion in 2025 to USD 1.49 Billion by 2035, as chronic wounds continue to rise and demand for advanced care ...

Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care ...

CMO Ray Turner discusses PriMatrix's non-cross-linked fetal bovine dermal matrix design, superior vascularization, and ...